Åter på nivåer från innan pandemin Arcomas omsättning för Q3 uppgick till 29 mkr, motsvarande en til...
EBIT SEK 12.9m (+24% vs. ABGSCe 10.4m) Q3 numbers imply EBIT upgrades of 4-3% Trading at 23x ’22e EV...
Fram Skandinavien’s local digital brands are growing rapidly.
Pihlajalinna’s Q3 revenue landed close to estimates, whereas profitability came in on the soft side.
Q3 beat driven by Investment Management AUM and postponed divestments lift ’23-24 EBIT 2023e EV/EBIT...
Eltel is likely to grow at high single-digit rates from here, but valuation already largely anticipa...
Obducat fortsätter att vinna fler affärer, där orderingången under årets tredje kvartal uppgick till...
Ascelia is reporting progress towards pivotal results with contained operational costs and cashflow.
Taaleri reported Q3 EBIT of EUR 18.5m, coming clearly below Refinitiv consensus at EUR 14.
Redeye comments on Medivir's third quarter report. There have been some positive developments in fo...
Company-compiled consensus and the share price had factored in a profit warning, but this did not pl...
Following BankNordik's Q3 report, we lift 2023E-24E adjusted EPS by ~11-15% to reflect a positive im...
Redeye provides its initial take on today’s announcement regarding the agreement with Wyld Networks ...
Both NII and NCI came in slightly better than expected in Q3.
Redeye comments on Vicore’s Q3 report, which came in as expected.
Addvise, en nischförvärvare av medicintekniska bolag, har via förvärv och hög organisk tillväxt ökat...
Q3 bjuder på rekordomsättning och svarta siffror på sista raden.
Redeye provides its comments on Optomed’s Q3 2022 report.
Redeye retains its positive view on CombinedX despite a soft Q3 report.
Med nio rapporterade månader i ryggen står det klart att Maven Wireless Sweden AB (”Maven” eller ”Bo...
